Introduction: Damage Control Surgery (DCS) is a surgical technique used to manage critically ill and injured patients. This study examines the most recent 10-y outcomes related to DCS, with the secondary goal of scrutinizing the outcomes after DCS across surgical theaters.
Methods: Studies published between 2012 and 2021 that described adult patients undergoing Abdominal DCS after traumatic injury were included. Outcomes were reported as medians-of-means and interquartile range.
Results: Fifty-two studies met inclusion criteria (9932 patients), all 52 were included in the Military versus Civilian comparison which includes 46 Civilian (9244 patients) and 6 Military (688 patients) studies. Forty-three studies were included in the United States (US) and non-US comparison, with 10 non-US (2092 patients), and 33 US (6572 patients) studies. Overall, study quality was low, the majority having a high or unclear risk of bias. Across all studies, the median 24-h mortality was 14% (5.1-21.2) and 30-d mortality was 17.9% (9.4-28.3). Between subgroups, the Military cohort had a 30-d mortality 9-fold lower than the Civilian cohort (2.1% versus 18.9%), and the non-US cohort had more than 3 times the 24-h mortality (23.8% versus 7.5%) and double the 30-d mortality (37.2% versus 14.6%) of the US cohort.
Conclusions: Striking disparities are seen within current literature as it relates to outcomes after DCS between Military and Civilian and US and non-US populations. Trauma surgeons both within the US and internationally may benefit from looking to their Military counterparts for guidance to better care patients requiring DCS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jss.2024.12.020 | DOI Listing |
J Inflamm Res
January 2025
Medical Imaging Centre, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Purpose: Immunometabolism is pivotal in rheumatoid arthritis (RA) pathogenesis, yet the intricacies of its pathological regulatory mechanisms remain poorly understood. This study explores the complex immunometabolic landscape of RA to identify potential therapeutic targets.
Patients And Methods: We integrated genome-wide association study (GWAS) data involving 1,400 plasma metabolites, 731 immune cell traits, and RA outcomes from over 58,000 participants.
J Viral Hepat
February 2025
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Dendritic cells are the most potent antigen-presenting cells in immune therapeutic approaches for chronic hepatitis B (CHB) infection. Here, we developed a clinical trial to evaluate the efficacy and safety of autologous HBV vaccine-pulsed DCs and their induced T cells (HPDCT) in CHB patients. This was a randomised, prospective, open-label, multicentre, superiority study and 309 treatment-naive CHB patients were divided into HPDCT plus nucleos(t)ide analogues (NAs) group (n = 84), NAs mono-therapy group (n = 82), HPDCT plus Peg-interferon (Peg-IFN) group (n = 69), Peg-IFN mono-therapy group (n = 74).
View Article and Find Full Text PDFPsychogeriatrics
January 2025
Department of Anesthesiology, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China.
Background: Postoperative delirium (POD) poses significant clinical challenges regarding its diagnosis and treatment. Identifying biomarkers that can predict and diagnose POD is crucial for improving patient outcomes.
Methods: To explore potential biomarkers for POD, we conducted bulk RNA sequencing (bulk-seq) on peripheral blood samples from POD patients and healthy controls.
Cancer Cell Int
January 2025
Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China.
Background: Patients with lung adenocarcinoma (LUAD) receiving drug treatment often have an unpredictive response and there is a lack of effective methods to predict treatment outcome for patients. Dendritic cells (DCs) play a significant role in the tumor microenvironment and the DCs-related gene signature may be used to predict treatment outcome. Here, we screened for DC-related genes to construct a prognostic signature to predict prognosis and response to immunotherapy in LUAD patients.
View Article and Find Full Text PDFJ Clin Neurosci
January 2025
Faculty of Health Sciences, Fenerbahçe University, Istanbul, Turkey.
Background: Lesions affecting the brain are variable and have multiple pathologies. Brain metastasis is a common entity of lesions that can be misleading in diagnosis. Brain metastasis affects the patient's life and survival in about 40% of cases; all patients with metastatic brain lesions are indicated for surgery, so proper diagnosis is crucial for each patient.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!